Antiangiogenic (in particular, anti-VEGF) therapy for diabetic nephropathy has been shown to be a promising strategy in many animal experiments, but some recent evidence raises concerns about its use in clinical practice. The gene discussed is VEGFA; the disease is diabetic kidney disease.